{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:19:23Z","timestamp":1794003563545,"version":"4.8.0"},"reference-count":43,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,10,27]],"date-time":"2012-10-27T00:00:00Z","timestamp":1351296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in 5 rheumatic diseases and 7 countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a multinational (Australia, France, Italy, Lebanon, Morocco, Spain, and The Netherlands) 4\u2010week cohort study involving 1,532 patients who were prescribed nonsteroidal antiinflammatory drugs for ankylosing spondylitis, chronic back pain, hand osteoarthritis, hip and\/or knee osteoarthritis, or rheumatoid arthritis. The MCII and PASS values were estimated with the 75th percentile approach for 4 generic outcomes: pain, patient global assessment, functional disability, and physician global assessment, all normalized to a 0\u2013100 score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For the whole sample, the estimated MCII values for absolute change at 4 weeks were \u221217 (95% confidence interval [95% CI] \u221218, \u221215) for pain; \u221215 (95% CI \u221216, \u221214) for patient global assessment; \u221212 (95% CI \u221213, \u221211) for functional disability assessment; and \u221214 (95% CI \u221215, \u221214) for physician global assessment. For the whole sample, the estimated PASS values were 42 (95% CI 40, 44) for pain; 43 (95% CI 41, 45) for patient global assessment; 43 (95% CI 41, 44) for functional disability assessment; and 39 (95% CI 37, 40) for physician global assessment. Estimates were consistent across diseases and countries (for subgroups \u226520 patients).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This work allows for promoting the use of values of MCII (15 of 100 for absolute improvement, 20% for relative improvement) and PASS (40 of 100) in reporting the results of trials of any of the 5 involved rheumatic diseases with pain, patient global assessment, physical function, or physician global assessment used as outcome criteria.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.21747","type":"journal-article","created":{"date-parts":[[2012,6,6]],"date-time":"2012-06-06T10:50:31Z","timestamp":1338979831000},"page":"1699-1707","source":"Crossref","is-referenced-by-count":373,"title":["Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study"],"prefix":"10.1002","volume":"64","author":[{"given":"F.","family":"Tubach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Martin\u2010Mola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bombardier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. T.","family":"Felson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hajjaj\u2010Hassouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Logeart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Matucci\u2010Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van de Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,10,27]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1063-4584(05)80101-3"},{"key":"e_1_2_8_3_2","first-page":"799","article-title":"Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis: consensus development at OMERACT III","volume":"24","author":"Bellamy N","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.8.552"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200305000-00006"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200203000-00006"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(03)00044-1"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022905"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015276414526"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199712060-00002"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00469-3"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90036-1"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023028"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22110"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/014662168300700301"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7549.1080"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-69"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.012"},{"key":"e_1_2_8_20_2","first-page":"1188","article-title":"Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders","volume":"34","author":"Tubach F","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_21_2","first-page":"2025","article-title":"Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues","volume":"32","author":"Tubach F","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090449"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22342"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.12.021"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23527"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20131"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22469"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780331101"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340502"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290816"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_8_34_2","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_35_2","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin A","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21615"},{"key":"e_1_2_8_37_2","first-page":"1833","article-title":"Validation of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthitis of the hip or knee","volume":"15","author":"Bellamy N","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-198303000-00004"},{"key":"e_1_2_8_39_2","first-page":"452","article-title":"Minimal clinically important difference module: summary, recommendations, and research agenda","volume":"28","author":"Wells G","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_8_40_2","first-page":"1110","article-title":"MCID\/low disease activity state workshop: low disease activity state in rheumatoid arthritis","volume":"30","author":"Wells G","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.09.012"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00204-3"},{"key":"e_1_2_8_43_2","first-page":"23","article-title":"Comparison of transformed visual analogue and native numerical rating scaled patient responses to the WOMAC Index","volume":"41","author":"Bellamy N","year":"2011","journal-title":"Int Med J"},{"key":"e_1_2_8_44_2","first-page":"1115","article-title":"MCID\/low disease activity state workshop: summary, recommendations, and research agenda","volume":"30","author":"Wells G","year":"2003","journal-title":"J Rheumatol"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.21747","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.21747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:42:02Z","timestamp":1759419722000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.21747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,27]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/acr.21747"],"URL":"https:\/\/doi.org\/10.1002\/acr.21747","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,27]]}}}